DOCSLIB.ORG

(12) United States Patent (10) Patent No.: US 9,095,563 B2 Sekura Et Al

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
(12) United States Patent (10) Patent No.: US 9,095,563 B2 Sekura Et Al US009095563B2 (12) United States Patent (10) Patent No.: US 9,095,563 B2 Sekura et al. (45) Date of Patent: Aug. 4, 2015 (54) TOPICAL TREATMENTS INCORPORATING A61E36/6 (2006.01) CANNABSSP. DERVED BOTANCAL DRUG A61E36/00 (2006.01) PRODUCT (52) U.S. Cl. CPC ............. A6 IK3I/352 (2013.01); A61 K3I/045 (71) Applicants: Ronald D. Sekura, Key Largo, FL (US); (2013.01); A61 K3I/047 (2013.01); A61 K Roscoe M. Moore, Jr., Rockville, MD 31/085 (2013.01); A61 K3I/235 (2013.01); (US) A6 IK3I/245 (2013.01); A61 K3I/573 (2013.01); A61 K36/00 (2013.01); A61 K (72) Inventors: Ronald D. Sekura, Key Largo, FL (US); 36/85 (2013.01); A6 IK36/6 (2013.01) Roscoe M. Moore, Jr., Rockville, MD (58) Field of Classification Search (US) CPC ...................................................... A61K 36/00 (*) Notice: Subject to any disclaimer, the term of this S. licati - - - - - file? - - - - - - - - - - - - -let - - - - - - - - - - -h hist 424f725 patent is extended or adjusted under 35 ee appl1cauon Ille Ior complete searcn n1Story. U.S.C. 154(b) by 0 days. (56) References Cited (21) Appl. No.: 14/498,555 U.S. PATENT DOCUMENTS (22) Filed: Sep. 26, 2014 6,630,507 B1 10/2003 Hampson et al. 7,026,360 B1 4/2006 Festo (65) Prior Publication Data 2008/0206161 A1 8/2008 Tamarkin et al. 2008, 0255224 A1 10, 2008 Blum US 2015/OO86494 A1 Mar. 26, 2015 OTHER PUBLICATIONS Related U.S. Application Data International Search Report and Written Opinion issued Dec. 29. (60) Provisional application No. 61/882,990, filed on Sep. 2014 in PCT/US2014/057801. 26, 2013. Primary Examiner — Michael Meller (51) Int. Cl. (74) Attorney, Agent, or Firm - Oblon, McClelland, Maier AOIN 65/00 (2009.01) & Neustadt, L.L.P. A6 IK3I/352 (2006.01) A 6LX3/573 (2006.01) (57) ABSTRACT A6 IK3I/085 (2006.01) A topical formulation comprising a Cannabis derived botani A6 IK3I/245 (2006.01) cal drug product, wherein the concentration of tetrahydrocan A6 IK3 L/047 (2006.01) nabinol, cannabidiol, or both in the topical formulation is A6 IK3I/235 (2006.01) greater than 2 milligrams per kilogram. A6 IK3I/045 (2006.01) A6 IK36/85 (2006.01) 30 Claims, 1 Drawing Sheet U.S. Patent Aug. 4, 2015 US 9,095,563 B2 US 9,095,563 B2 1. 2 TOPCAL TREATMENTS INCORPORATING are useful as tissue protectants, such as neuroprotectants and CANNABSSP DERVED BOTANCAL DRUG cardioprotectants. The compounds and compositions are dis PRODUCT closed to be used in the treatment of acute ischemic neuro logical insults or chronic neurodegenerative diseases. The CROSS-REFERENCE TO RELATED disclosed compositions include cannabidiol and other can APPLICATIONS nabinoids, and the compositions are disclosed to include THC in amounts that do not promote psychoactive or psychotoxic This application claims the benefit of U.S. Provisional effects. Accordingly, there is no disclosure of topical compo Application No. 61/882,990, filed on Sep. 26, 2013, which is sitions that include THC in amounts that exceed the detection herein incorporated by reference in its entirety. 10 limit of THC. In view of the foregoing, there is a need for topical formu FIELD OF THE INVENTION lations that comprise a Cannabis derived botanical drug prod This invention relates to topical formulations that comprise uct that take advantage of diverse pharmacologic activities, a Cannabis derived botanical drug product, methods of mak 15 that are beyond and unforeseen from those described in U.S. ing the topical formulations, and methods of using the topical Pat. No. 6,630.507 B1, in treatment of dermatologic and other formulations in treating dermatological diseases. diseases. We also define that the major cannabinoids are present in our products at concentrations exceeding the com BACKGROUND OF THE INVENTION monly applied maximum levels that define cannabis derived products, such as hemp oil, legal for non-drug use can provide The botanical genus Cannabis includes the species indica unexpected and highly beneficial treatments for a wide vari and sativia. Within these species multiple distinct varieties ety of diseases. and strains have been and continue to be developed. The genus known produce more than 480 different chemical sub BRIEF SUMMARY OF THE INVENTION stances. Among these chemicals approximately 80 distinct 25 entities exist which are classified as cannabinoids. The two One object of the invention is to provide a topical prepara species differ in the amount of tetrahydrocannabinol (THC) tion comprising a Cannabis derived botanical drug product produced. Cannabis sativia produces higher levels of THC. such that the concentration of tetrahydrocannabinol in the The psychotropic affects associated with THC have made the final product is greater than 2 milligrams per kilogram. Other sativia species preferred as a recreational Substance and for 30 objects of the invention include methods of making the topi medicinal use where the psychotropic effect is desired. Not cal preparations and methods of using the topical prepara with-standing THC and other chemical entities produced by tions to treat dermatological diseases. the sativia species have significant and diverse pharmacologi cal action. BRIEF DESCRIPTION OF THE DRAWINGS The indica species is cultivable in cooler climates and 35 produce more cannabidiol (CBD) than THC. This allows FIG. 1 shows an area of skin affected by plaque psoriasis. production of extracts with low THC. The seeds from Can FIG. 2 shows the results of treating psoriasis affected area nabis species are used to produce hemp oil which is used by application of topical formulation comprising a Cannabis industrially and also as a nutritional Supplement. derived botanical drug product according to the present Cannabis derived materials which may contain THC and 40 invention. CBD in addition to numerous natural substances produced by the plants have been reported to have diverse pharmacologi EMBODIMENTS OF THE PRESENT cal activities that include analgesic, anti-inflammatory, anti INVENTION cancer, antibiotic, and anti-oxidant activity. In most jurisdictions throughout the world, including the 45 One embodiment of the present invention is 1 a topical United States, cannabinoids (which include THC, structur formulation comprising a Cannabis derived botanical drug ally related compounds, and in Some instances CBD) are product, wherein the concentration of tetrahydrocannabinol controlled Substances and use for medical purposes has been in the topical formulation is greater than 2 milligrams per discouraged. Since some products derived from cannabis kilogram. species are economically important (e.g. hemp oil) maximum 50 Another embodiment of the present invention is 2 a topi levels for cannabinoids in products have been set. In Cana cal formulation comprising a Cannabis derived botanical dian hemp seed oil THC levels are usually below detection drug product, wherein the concentration of cannabidiol in the limit of 4 ppm (parts per million, or 4 mg/kg). Legal limit for topical formulation is greater than 2 milligrams per kilogram. THC content in foodstuffs in Canada is 10 ppm. Some Euro Another embodiment of the present invention is 3 a topi pean countries have limits of 5 ppm or none-detected, some 55 cal formulation comprising a Cannabis derived botanical EU countries do not have such limits at all. drug product, wherein the concentration of each, cannabidiol Relaxation of laws limiting the use of marijuana and thus and tetrahydrocannabinol, in the topical formulation is cannabinoid containing products, in some jurisdictions (e.g. greater than 2 milligrams per kilogram. as of 2013 medical marijuana is considered legal in 20 states Another embodiment of the present invention is 4 a topi and the District of Columbia) has opened the door to encour 60 cal formulation according to 1, 2, or 3, which further age development of new cannabinoid containing products. To comprises hydrocortisone or any steroid within Groups I to a large extent major focus has been directed at Systemically VII in the US classification system in a therapeutically effec administered formulations and formulations taking advan tive amount. tage of psychotropic activities or use of cannabinoids as anti Another embodiment of the present invention is 5 a topi oxidants and neuroprotectants. 65 cal formulation according to 1, 2, or 3, which further U.S. Pat. No. 6,630,507, incorporated herein by reference, comprises an antibiotic compound in a therapeutically effec discloses pharmaceutical compounds and compositions that tive amount. US 9,095,563 B2 3 4 Another embodiment of the present invention is 6 a topi DETAILED DESCRIPTION OF THE INVENTION cal formulation according to 1, 2, or 3, which further comprises an antiseptic compound in a therapeutically effec Unless indicated otherwise, the indefinite articles “a” and tive amount. “an are synonymous with “at least one' or “one or more.” Another embodiment of the present invention is 7 a topi Unless indicated otherwise, definite articles used herein, such cal formulation according to 1, 2, or 3, which further as “the also include the plural of the noun. Terms used herein comprises an antifungal compound in a therapeutically effec Such as "comprising.” “consisting essentially of” and “con tive amount. sisting of have their ordinary and customary meaning under Another embodiment of the present invention is 8a topi U.S. patent law. Unless otherwise indicated, the transitional cal formulation according to 1, 2, or 3, which further 10 comprises an anti-acne agent in a therapeutically effective term "comprising is synonymous with “including.” “con amount. taining,” or “characterized by and is inclusive or open-ended Another embodiment of the present invention is 9 a topi and does not exclude additional, unrecited elements or cal formulation according to 1, 2, or 3, which further method stages. Unless otherwise indicated, the transitional comprises a soothing, Smoothing, moisturizing or protective 15 term “consisting essentially of limits the scope of the claim agent in a therapeutically effective amount.
Load more

Recommended publications
  • (Schizotrypanum) Cruzi in Dog Hosts Paulo Marcos Da Matta Guedes,1 Julio A
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Nov. 2004, p. 4286–4292 Vol. 48, No. 11 0066-4804/04/$08.00ϩ0 DOI: 10.1128/AAC.48.11.4286–4292.2004 Copyright © 2004, American Society for Microbiology. All Rights Reserved. Activity of the New Triazole Derivative Albaconazole against Trypanosoma (Schizotrypanum) cruzi in Dog Hosts Paulo Marcos da Matta Guedes,1 Julio A. Urbina,2 Marta de Lana,3 Luis C. C. Afonso,1 Vanja M. Veloso,1 Washington L. Tafuri,1 George L. L. Machado-Coelho,4 Egler Chiari,5 and Maria Terezinha Bahia1* Departamento de Cieˆncias Biolo´gicas,1 Departamento de Ana´lises Clínicas,3 and Departamento de Farma´cia,4 Universidade Federal de Ouro Preto, Ouro Preto, and Departamento de Parasitologia, Universidade Federal de Minas Gerais, Belo Horizonte,5 Minas Gerais, Brazil, and Centro de Biofísica y Bioquímica, Instituto Venezolano de Investigaciones Científicas, Caracas, Venezuela2 Received 25 March 2004/Returned for modification 8 June 2004/Accepted 20 July 2004 Albaconazole is an experimental triazole derivative with potent and broad-spectrum antifungal activity and a remarkably long half-life in dogs, monkeys, and humans. In the present work, we investigated the in vivo activity of this compound against two strains of the protozoan parasite Trypanosoma (Schizotrypanum) cruzi, the causative agent of Chagas’ disease, using dogs as hosts. The T. cruzi strains used in the study were previously characterized (murine model) as susceptible (strain Berenice-78) and partially resistant (strain Y) to the drugs currently in clinical use, nifurtimox and benznidazole. Our results demonstrated that albaconazole is very effective in suppressing the proliferation of the parasite and preventing the death of infected animals.
    [Show full text]
  • PHARMACEUTICAL APPENDIX to the TARIFF SCHEDULE 2 Table 1
    Harmonized Tariff Schedule of the United States (2020) Revision 19 Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2020) Revision 19 Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names INN which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service CAS registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known.
    [Show full text]
  • WO 2014/195872 Al 11 December 2014 (11.12.2014) P O P C T
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2014/195872 Al 11 December 2014 (11.12.2014) P O P C T (51) International Patent Classification: (74) Agents: CHOTIA, Meenakshi et al; K&S Partners | Intel A 25/12 (2006.01) A61K 8/11 (2006.01) lectual Property Attorneys, 4121/B, 6th Cross, 19A Main, A 25/34 (2006.01) A61K 8/49 (2006.01) HAL II Stage (Extension), Bangalore 560038 (IN). A01N 37/06 (2006.01) A61Q 5/00 (2006.01) (81) Designated States (unless otherwise indicated, for every A O 43/12 (2006.01) A61K 31/44 (2006.01) kind of national protection available): AE, AG, AL, AM, AO 43/40 (2006.01) A61Q 19/00 (2006.01) AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, A01N 57/12 (2006.01) A61K 9/00 (2006.01) BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, AOm 59/16 (2006.01) A61K 31/496 (2006.01) DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, (21) International Application Number: HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, PCT/IB20 14/06 1925 KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, (22) International Filing Date: OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, 3 June 2014 (03.06.2014) SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, (25) Filing Language: English TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
    [Show full text]
  • A Ketoconazole Susceptibility Test for Malassezia Pachydermatis Using Modified Leeming–Notman Agar
    Journal of Fungi Article A Ketoconazole Susceptibility Test for Malassezia pachydermatis Using Modified Leeming–Notman Agar Bo-Young Hsieh 1,2, Wei-Hsun Chao 3, Yi-Jing Xue 2 and Jyh-Mirn Lai 2,* 1 Lugu Township Administration, Nanto County 55844, Taiwan; [email protected] 2 College of Veterinary Medicine, National Chiayi University, No. 580, XinMin Rd., Chiayi City 60054, Taiwan; [email protected] 3 Department of Hospitality Management, WuFung University, Chiayi City 60054, Taiwan; [email protected] * Correspondence: [email protected]; Tel.: +886-5-2732920; Fax: +886-5-2732917 Received: 18 September 2018; Accepted: 14 November 2018; Published: 16 November 2018 Abstract: The aim of this study was to establish a ketoconazole susceptibility test for Malassezia pachydermatis using modified Leeming–Notman agar (mLNA). The susceptibilities of 33 M. pachydermatis isolates obtained by modified CLSI M27-A3 method were compared with the results by disk diffusion method, which used different concentrations of ketoconazole on 6 mm diameter paper disks. Results showed that 93.9% (31/33) of the minimum inhibitory concentration (MIC) values obtained from both methods were similar (consistent with two methods within 2 dilutions). M. pachydermatis BCRC 21676 and Candida parapsilosis ATCC 22019 were used to verify the results obtained from the disk diffusion and modified CLSI M27-A3 tests, and they were found to be consistent. Therefore, the current study concludes that this new novel test—using different concentrations of reagents on cartridge disks to detect MIC values against ketoconazole—can be a cost-effective, time-efficient, and less technically demanding alternative to existing methods.
    [Show full text]
  • WO 2015/134796 Al 11 September 2015 (11.09.2015) P O P C T
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2015/134796 Al 11 September 2015 (11.09.2015) P O P C T (51) International Patent Classification: AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, A61K 9/14 (2006.01) A61K 47/10 (2006.01) BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, A61K 9/16 (2006.01) DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, (21) International Application Number: KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, PCT/US20 15/0 19042 MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, (22) International Filing Date: PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, 5 March 2015 (05.03.2015) SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (25) Filing Language: English (84) Designated States (unless otherwise indicated, for every (26) Publication Language: English kind of regional protection available): ARIPO (BW, GH, (30) Priority Data: GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, 61/948,173 5 March 2014 (05.03.2014) US TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, 14/307,138 17 June 2014 (17.06.2014) US TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, (71) Applicant: PROFESSIONAL COMPOUNDING CEN¬ LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, TERS OF AMERICA [US/US]; 9901 South Wilcrest SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, Drive, Houston, TX 77099 (US).
    [Show full text]
  • WO 2018/102407 Al 07 June 2018 (07.06.2018) W !P O PCT
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2018/102407 Al 07 June 2018 (07.06.2018) W !P O PCT (51) International Patent Classification: TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, C07K 7/60 (2006.01) G01N 33/53 (2006.01) EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, CI2Q 1/18 (2006.01) MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, (21) International Application Number: KM, ML, MR, NE, SN, TD, TG). PCT/US2017/063696 (22) International Filing Date: Published: 29 November 201 7 (29. 11.201 7) — with international search report (Art. 21(3)) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/427,507 29 November 2016 (29. 11.2016) US 62/484,696 12 April 2017 (12.04.2017) US 62/53 1,767 12 July 2017 (12.07.2017) US 62/541,474 04 August 2017 (04.08.2017) US 62/566,947 02 October 2017 (02.10.2017) US 62/578,877 30 October 2017 (30.10.2017) US (71) Applicant: CIDARA THERAPEUTICS, INC [US/US]; 63 10 Nancy Ridge Drive, Suite 101, San Diego, CA 92121 (US). (72) Inventors: BARTIZAL, Kenneth; 7520 Draper Avenue, Unit 5, La Jolla, CA 92037 (US). DARUWALA, Paul; 1141 Luneta Drive, Del Mar, CA 92014 (US). FORREST, Kevin; 13864 Boquita Drive, Del Mar, CA 92014 (US).
    [Show full text]
  • Antifungal Reference Materials
    Antifungal reference materials Antifungal (antimycotic) agents These infections can be potentially lethal in are used for prophylaxis and immunocompromised patients such as those with HIV/AIDS or transplant recipients taking treatment of fungal, yeast and medications to suppress their immune system. mould infections. These can range The successful management of invasive from superficial infections including fungal infections poses a difficult challenge to athlete’s foot, ringworm, vaginal clinicians. Antifungal agents have important thrush and fungal nail infections, limitations in their spectrum of activity and can be associated with unpredictable bioavailability, through to the more serious significant pharmacokinetic variability, intolerance, invasive infections such as systemic considerable acute and chronic toxicity and candidiasis, pulmonary aspergillosis potential for drug-drug interactions. Therapeutic and cryptococcal meningitis. Drug Monitoring can assist in optimising the efficacy and safety of certain antifungal therapy. LGC now offer an extensive range of antifungal agents. LGC Quality - ISO Guide 34 • GMP/GLP • ISO 9001 • ISO/IEC 17025 • ISO/IEC 17043 Reference materials Product code Description Unit 1 Unit 2 Imidazoles TRC-B690273 Butoconazole Nitrate 10 mg 100 mg TRC-B690272 Butoconazole (rac)-d5 Nitrate 1 mg 10 mg LGCFOR0015.00 Clotrimazole 10 mg TRC-C587402 Clotrimazole-d5 1 mg 10 mg LGCFOR0524.00 Econazole Nitrate 10 mg TRC-F279250 Fenticonazole Nitrate 100 mg 1 g LGCFOR0541.00 Isoconazole Nitrate 10 mg LGCFOR0145.00
    [Show full text]
  • New-Generation Triazole Antifungal Drugs: Review of the Phase II and III Trials
    Review: Clinical Trial Outcomes New-generation triazole antifungal drugs: review of the Phase II and III trials Clin. Invest. (2011) 1(11), 1577–1594 In this article, the pharmacological, microbiological and clinical development Corrado Girmenia†1 & Erica Finolezzi1 progress from Phase II and III clinical trials with the new generation triazoles 1Dipartimento di Ematologia, Oncologia, albaconazole, isavuconazole, posaconazole, ravuconazole and voriconazole Anatomia Patologica & Medicina Rigenerativa, are reviewed. These drugs exhibit a favorable toxicity profile and possess high Azienda Policlinico Umberto I, Via Benevento 6, activity against resistant and emerging fungal pathogens. Pharmacokinetic 00161, Rome, Italy †Author for correspondence: may be affected by variability in metabolism and/or gastrointestinal Tel.: +39 0685 7951 absorption. Only voriconazole and posaconazole have been adequately Fax: +39 0644 241 984 investigated and are now indicated in the treatment and prophylaxis of E-mail: [email protected] invasive fungal diseases. Other triazoles; albaconazole, isavuconazole and ravuconazole are under development; therefore, their future use is unknown. Keywords: albaconazole • antifungal prophylaxis • antifungal therapy • isavuconazole • Phase II and III trials • posaconazole • ravuconazole • triazoles • voriconazole Opportunistic invasive fungal diseases (IFDs) are a major cause of morbidity and mortality in immunocompromised patients, particularly those affected by hematological diseases and cancer, and those undergoing transplant procedures or prolonged immunosuppressive therapy. Considerable progress in treating systemic mycoses has been achieved in recent years through better use of old antifungal agents and through development of new drugs in association with more advanced diagnostic procedures. The search for new antifungal strategies has been mainly focused on the reduction of toxicity, enhancement of bioavailability, improvement of the antifungal spectrum and counteraction of resistance.
    [Show full text]
  • Malassezia Furfur Javier Esteban Mussin1* , María Virginia Roldán2, Florencia Rojas1, María De Los Ángeles Sosa1, Nora Pellegri2 and Gustavo Giusiano1
    Mussin et al. AMB Expr (2019) 9:131 https://doi.org/10.1186/s13568-019-0857-7 ORIGINAL ARTICLE Open Access Antifungal activity of silver nanoparticles in combination with ketoconazole against Malassezia furfur Javier Esteban Mussin1* , María Virginia Roldán2, Florencia Rojas1, María de los Ángeles Sosa1, Nora Pellegri2 and Gustavo Giusiano1 Abstract Malassezia furfur is lipophilic and lipid-dependent yeast, inhabitant of human skin microbiota associated with several dermal disorders. In recent years, along with the advances in nanotechnology and the incentive to fnd new antimi- crobial drugs, there has been a growing interest in the utilization of nanoparticles for the treatment of skin microbial infections. This work aimed to study the in vitro inhibitory activity of silver nanoparticles (AgNP) against 41 M. furfur clinical isolates, visualize the interaction between AgNP-Malassezia, evaluate the synergism with ketoconazole (KTZ) and to produce an antimicrobial gel of AgNP–KTZ. The synthesized AgNP were randomly distributed around the yeast surface and showed a fungicidal action with low minimal inhibitory concentration values. AgNP showed no antago- nistic efect with KTZ. The broad-spectrum antimicrobial property with fungicidal action of AgNP and its accumula- tion in afected areas with a sustained release profle, added to the great antifungal activity of KTZ against Malassezia infections and other superfcial mycoses, allowed us to obtain a gel based on carbopol formulated with AgNP–KTZ with the potential to improve the topical therapy of superfcial malasseziosis, reduce the number of applications and, also, prevent the recurrence. Keywords: Malassezia, Nanoparticles, Antifungal activity, Synergy Introduction papillomatosis, and neonatal pustulosis (Giusiano 2006; Yeasts of Malassezia genus are normal inhabitants of the Boekhout et al.
    [Show full text]
  • Clinical Manifestations, Treatment and Outcome of Paecilomyces Lilacinus Infections F
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Elsevier - Publisher Connector REVIEW 10.1111/j.1469-0691.2006.01481.x Clinical manifestations, treatment and outcome of Paecilomyces lilacinus infections F. J. Pastor and J. Guarro Unitat de Microbiologia, Facultat de Medicina I Cie`ncies de la Salut, Universitat Rovira i Virgili, Reus, Spain ABSTRACT The fungus Paecilomyces lilacinus is an emerging pathogen that causes severe human infections, including devastating oculomycosis. Usually, it shows low susceptibility to conventional antifungal drugs in vitro, and variable susceptibility to novel triazoles. A review of the published literature identified 119 reported cases of human infection by P. lilacinus between 1964 and 2004. Most were cases of oculomycosis (51.3%), followed by cutaneous and sub-cutaneous infections (35.3%), and a smaller group of miscellaneous infections (13.4%). Lens implantation is the most frequent predisposing factor for oculomycosis. Cutaneous and sub-cutaneous infections occur mainly in solid organ and bone marrow transplant recipients, although surgery and primary or acquired immunodeficiency are also relevant predisposing factors. Infections in apparently immunocompetent patients have also been reported. Surgical debride- ment combined with antifungal drug therapy, or the correction of predisposing factors, such as neutropenia, are usually required to obtain improvement. Treatment with traditional antifungal drugs often fails. Voriconazole has demonstrated good activity in both cutaneous and ocular infections in the few cases in which this drug has been used. The new triazoles ravuconazole and posaconazole show good in- vitro activity against P. lilacinus and could be promising therapeutic alternatives. Keywords Fungal infections, oculomycosis, Paecilomyces lilacinus, review, risk-factors, voriconazole Accepted: 1 December 2005 Clin Microbiol Infect 2006; 12: 948–960 Paecilomyces is a hyaline hyphomycete that INTRODUCTION exists worldwide.
    [Show full text]
  • Recent Developments in Antifungal Agents
    International Journal of Pharmacy and Pharmaceutical Sciences Academic Sciences ISSN- 0975-1491 Vol 4, Suppl 4, 2012 Review Article RECENT DEVELOPMENTS IN ANTIFUNGAL AGENTS 1SMITA TALAVIYA, 2FALGUNI MAJMUDAR *1Department of Pharmaceutical Chemistry, K. B. Raval College of Pharmacy, Gandhinagar, Gujarat, 2Department of Pharmacology, Smt. N.H.L. Municipal Medical College, Ahmedabad, Gujarat, India. Email: [email protected] Received: 23 Feb 2012, Revised and Accepted: 30 Mar 2012 ABSTRACT Life threatening invasive fungal infections is a major problem in immunocompromised patients. Standard antifungal agents so far have been quite successful, but some of them have limited use because of toxicity and drug resistance and even their clinical efficacy in some invasive fungal infections, such as aspergillosis and fusariosis, is not optimal. Among the several widely used antifungal drugs, azoles are most frequently prescribed in various types of fungal infections. Some new antifungal agents have demonstrated therapeutic potential and may provide additional options for the treatment of fungal infections and may help to overcome the limitations of current drugs. This review briefly discusses currently available antifungal agents and primarily concerns with recent developments in antifungal agents including lipid formulation of polyenes, novel azoles, echinocandins, sordarins, nikkomycins, monoclonal antibody, aminocandin and interferon- -1b. Keywords: Antifungal agents, Newer approaches, Azoles, Echinocandins. γ INTRODUCTION for treatment of aspergillosis under optimal conditions.14 The increase in zygomycosis in the hematopoietic cell transplantation The incidences of invasive fungal infections (IFIs) have increased setting can be due to the increased use of Voriconazole.12 gravely since 1980s, worldwide, especially in the immunocompromised persons.1 IFIs are characterized by high Limited pediatric data are available comparing antifungal agents in morbidity and mortality.
    [Show full text]
  • Stembook 2018.Pdf
    The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances FORMER DOCUMENT NUMBER: WHO/PHARM S/NOM 15 WHO/EMP/RHT/TSN/2018.1 © World Health Organization 2018 Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; https://creativecommons.org/licenses/by-nc-sa/3.0/igo). Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: “This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition”. Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization. Suggested citation. The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances. Geneva: World Health Organization; 2018 (WHO/EMP/RHT/TSN/2018.1). Licence: CC BY-NC-SA 3.0 IGO. Cataloguing-in-Publication (CIP) data.
    [Show full text]